Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility

"Double-hit" and "double-expressor" lymphomas represent distinct but overlapping subsets of aggressive B-cell non-Hodgkin lymphoma. The high rates of bone marrow involvement by these lymphomas pose a major therapeutic challenge due to the chemotherapy-resistant nature of the bone...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Craig, Jeffrey W., Mina, Michael J., Crombie, Jennifer L., LaCasce, Ann S., Weinstock, David M., Pinkus, Geraldine S., Pozdnyakova, Olga
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6051601/
https://ncbi.nlm.nih.gov/pubmed/30020951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0199708
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars